The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 41.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (27 analysts) rates it buy, with a mean price target of $184.
Palantir Technologies
PLTR · a US exchange · USD · Market cap $418.0B · 4,395 employees
Palantir Technologies Inc.
FAIL · Does not pass the screenAt the last full screen
2026-08-20
Screened 2026-08-20 · the tape above runs as of 23:26 UTC · 4 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
This name holds its markup label.
Palantir Technologies holds its Markup at $173.96. Consolidating, no directional conviction, held for 8 days.
| Phase | Markup |
| Quantitative state | Consolidating, no directional conviction, held for 8 days |
| Price at the screen | $173.96 |
| Valuation | 148.68 trailing · 75.17 forward price to earnings |
| Values screen | FAIL · score 10.0 |
| Beta | 1.56 |
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 2.58% | Below 33% | Interest-bearing debt is just 2.6% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 64.64% | Below 33% | Interest-bearing cash and securities are 64.6% of assets, above the one-third limit. | Fail |
| Receivables | 27.71% | Below 49% | Money owed to the company is 27.7% of assets, under the 49% limit. | Pass |
| Revenue purity | 5.12% | Below 5% | 5.1% of revenue comes from non-compliant sources, over the 5% line. | Fail |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is WorthThe Fair Value Range
Our framework reads AVOID: it trades above our $132.09 fair value estimate, strong competitive moat, 92.80% revenue growth.
Fair value range in USD, drawn from the 2026-08-20 screen. The gold marker is the market price at the same screen. The price runs 24.1% above the base estimate.
Third-party analyst targets: 27 covering, consensus Buy. The average target sits +17% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & ProjectionsWhere it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-08-20 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsPalantir's Ethical Woes Despite High Praise
Palantir Technologies, often discussed as a tech darling, is the go-to for the intelligence community's counterterrorism efforts. Imagine a digital detective kit that helps solve complex crimes - that's Palantir. But the reason we're passing on it? Not the business fundamentals, but ethical considerations and high valuation. Despite its 93% revenue growth and robust profit margin of 49%, Palantir fails our ethical screen due to its interest-bearing securities. Why it stands out would otherwise be its strong moat and high ROE of 38%, which speaks to its profitability and efficiency.
However, at a price of $173.96 and a forward P/E of 75.2x, the market is pricing in an extremely high future earnings expectation. In comparison, our fair value is significantly lower at $132.09, indicating a margin of safety of -24%. Risk sits in the high valuation and the ethical failings - a double whammy that makes us cautious. Analysis, not advice.
| Forward P/E | 75.2xfairly priced for its growth rate |
| Trailing P/E | 148.7xexpensive: the price assumes strong growth ahead |
| EPS, trailing | 1.17 |
| EPS, forward | 2.31 |
| Revenue growth | +92.8%growing very fast |
| Profit margin | 49.0%highly profitable on every dollar of sales |
| Return on equity | 38.1%an exceptional return on shareholder capital |
| FCF yield | 0.52% |
| Debt to equity | 2.14heavy leverage: higher risk if revenue softens |
| Current ratio | 7.23comfortably covers its short-term bills |
| Beta | 1.56much more volatile than the market |
| Short interest, float | 0.03% |
| 52-week range | 106.37 - 207.52 |
| Moat | STRONG |
| Market cap | $418.0B |
| Employees | 4,395 |
The risks · The things to watch: it already moves more than the market on an average day; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradePLTR trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (27 analysts) rates it buy, with a mean price target of $184. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (27 analysts) rates it buy, with a mean price target of $184. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (27 analysts) rates it buy, with a mean price target of $184. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (27 analysts) rates it buy, with a mean price target of $184. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (27 analysts) rates it buy, with a mean price target of $184. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (27 analysts) rates it buy, with a mean price target of $184. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 7.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (27 analysts) rates it buy, with a mean price target of $184. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 2.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 49%. The street (27 analysts) rates it buy, with a mean price target of $184.
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Inside Zeta's Transformation From Hopeful Do-Over To Surging AI Marketing Stock Investor's Business Daily · 12h ago
- Palantir (PLTR) Stock Fair Value Edges Higher After Strong Q2 And Raised Guidance Simply Wall St. · 12h ago
- 3 Reasons PLTR Has Explosive Upside Potential StockStory · 12h ago
- Palantir just won the Army and lost Michael Burry TheStreet · 14h ago
- SCHG Owns More Apple Than Tesla, Meta and Palantir Combined. Is That Why Growth Investors Are Falling Behind? 24/7 Wall St. · 17h ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-05 | Stat Lauren Elaina Friedman | Dir | S - Sale | 3,032 | $500,280 |
| 2026-05-15 | MOORE ALEXANDER D | Director | 16,000 | $2,144,663 | |
| 2026-04-24 | BUCKLEY JEFFREY JOHANSING | Officer | 21,141 | · | |
| 2026-04-15 | MOORE ALEXANDER D | Director | 16,000 | $2,230,580 | |
| 2026-03-16 | MOORE ALEXANDER D | Director | 16,000 | $2,438,623 | |
| 2026-03-02 | THIEL PETER A. J.D. | Director | 2,000,000 | $289,707,507 | |
| 2026-02-26 | STAT LAUREN ELAINA FRIEDMAN | Director | 7,000 | · | |
| 2026-02-24 | BUCKLEY JEFFREY JOHANSING | Officer | 3,936 | $520,601 | |
| 2026-02-20 | SANKAR SHYAM | Chief Technology Officer | 168,004 | · | |
| 2026-02-20 | KARP ALEXANDER C. | Chief Executive Officer | 493,025 | · |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 9 Jan2026 | Michael Rulli | Republican | buy | 1K–15K |
| 7 Jul2026 | Ro Khanna | Democrat | buy | 1K–15K |
| 7 Jul2026 | Ro Khanna | Democrat | buy | 1K–15K |
| 6 May2026 | Michael Rulli | Republican | sell | 1K–15K |
| 27 Mar2026 | Alan Armstrong | Republican | buy | 15K–50K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $136.89 | -4.6% | · | $954 | -4.6% |
| 2 months | $128.06 | +1.9% | · | $1,019 | +1.9% |
| 3 months | $153.50 | -15.0% | · | $851 | -15.0% |
| 6 months | $187.54 | -30.4% | · | $696 | -30.4% |
| 1 year | $132.81 | -1.7% | · | $983 | -1.7% |
| 2 years | $23.13 | +464.4% | · | $5,644 | +464.4% |
| 3 years | $15.02 | +769.2% | · | $8,692 | +769.2% |
| 5 years | $24.67 | +429.2% | · | $5,292 | +429.2% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever PLTR does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.